Abstract
Purpose: 2018 ASCO CAP testing guidelines for HER2 recommended a change from ‘positive’ to ‘negative’ in cases of IHC 2+, FISH HER2/CEP17 ratio ≥2.0 and HER2 copy number <4 – known as ‘group 2’ cases [1,2]. In the UK, these cases are positive, but borderline amplified with uncertain benefit of anti-HER2 treatment [3]. Ahead of a forthcoming review of HER2 testing guidelines by the UK National Coordinating Committee for Breast Pathology, we aimed to identify real-world data on group 2 patients, including frequency, characteristics and outcomes in those treated with anti-HER2.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
